|
[1]Fried MW, Shiffman ML, Reddy KR, et al.Peginterferon alfa-2aplus ribavirin for chronic hepatitis C virus infection[J].N Engl JMed, 2002, 347 (13) ∶975-982.
|
|
[2]Cacoub P, Renou C, Rosenthal E, et al.Extrahepatic manifestationsassociated with hepatitis C virus infection:a prospective multi-cen-ter study of 321 patients[J].Medicine (Baltimore) , 2000, 79 (1) ∶47-56.
|
|
[3]Zoulim F, Chevallier M, Maynard M, et al.Clinical consequencesof hepatitis C virus infection[J].Rev Med Virol, 2003, 13 (1) ∶57-68.
|
|
[4]EL-Serag HB, Hampel H, Yeh C, et al.Extrahepatic manifesta-tions of hepatitis C among United States male veterans[J].Hepatol-ogy 2002, 36 (6) ∶1439-1445.
|
|
[5]Zhu Q, Guo JT, Seeger C.Replication of hepatitis C virus subge-nomes in nonhepatic epithelial and mouse hepatoma cells[J].Vir-ol, 2003, 77 (17) ∶9204-9210.
|
|
[6]Goutagny N, Fatmi A, De Ledinghen V, et al.Evidence of viralreplication in circulating dendritic cells during hepatitis C virus in-fection[J].J Infectious Diseases, 2003, 187 (12) ∶1951-1958.
|
|
[7]Agnello V, De Rosa FG.Extrahepatic disease manifestations ofHCV infection:Some current issues[J].Hepatol, 2004, 40 (2) ∶341-352.
|
|
[8] 中华医学会.丙型肝炎防治指南[J].中华肝脏病杂志, 2004, 9 (84) ∶194-198.
|
|
[9]Primo Vera J.Pegylated interferon-induced diabetes mellitus type1 in two patients with chronic hepatitis C[J].Gastroenterol Hepa-tol, 2004, 27 (2) ∶69.
|
|
[10]Gatselis NK, Georgiadou SP, Tassopoulos N, et al.Impact of parie-tal cell autoantibodies and non-organ-specific autoantibodies onthe treatment outcome of patients with hepatitis C virus infection:apilot study[J].World J Gastroenterol, 2005, 11 (4) ∶482-487.
|
|
[11]Kato-Motozaki Y, Komai K, Takahashi K, et al.Polyethylene gly-col interferon alpha-2b-induced immune-mediated polyradicu-loneuropathy[J].Intern Med, 2009, 48 (7) ∶569-572.
|
|
[12]Rowan AG, Fletcher JM, Ryan EJ, et al.Hepatitis C virus-specif-ic Th17 cells are suppressed by virus-induced TGF-beta[J].JImmunol, 2008, 181 (7) ∶4485-4494.
|
|
[13]ParanóR, Schinoni MI, de Freitas LA, et al Anti-Golgi complexantibodies during pegylated-interferon therapy for hepatitis C[J].Liver Int, 2006, 26 (9) ∶1148-1154.
|
|
[14]Cresta P, Musset L, Cacoub P, et al Response to interferon al-phatherapy and disappearance of cryoglobulinemia in patients infec-ted by hepatitis C virus[J].Gut, 1999, 45 (1) ∶122-128.
|
|
[15]Wasmuth HE, Stolte C, Geier A, et al.The presence of non-or-gan-specific autoantibodies is associated with a negative responseto combination therapy with interferon and ribavirin for chronic hep-atitis C[J].BMC infect Dis, 2004, 4∶4.
|
|
[16]Bayraktar y, Bayratar M, Gurakar A, et al.A comparison of theprevalence of autoantibodies in individuals with chronic hepatitis Cand those with autoimmune hepatitis:the role of interferon in thedevelopment of autoimmune diseases[J].Hepatogastroenterology, 1997, 44 (14) ∶417-425.
|
DownLoad: